Contact Us | Site Map | SEARCH
 
About HDNAbout RhophylacThe Rhophylac PromiseProfessional ResourcesClinical ResourcesMedical Advisory PanelsTeleconferencesTeleconferencesOrdering and ReimbursementPatient EducationRequest More InformationImportant Safety InformationPrescribing Information

Teleconferences

You are invited to join a distinguished team of your colleagues in an interactive telephone conference series for healthcare professionals. Conferences will be held in the evening on the dates and times noted on this calendar. The entire program will last approximately 1 hour. Each session will feature a lecture by a distinguished faculty member, who will present a clinical overview on the following specialty-related topics:

Topic One:

Optimization of Rh Prophylaxis Treatment: IV Issues and Patient Comfort -
Conference designed for issues in nursing presented by a registered nurse thought leader

Topic Two:

Mismatched Blood Transfusion -
Conference designed for and relevant to blood bankers and presented by a blood bank thought leader

Topic Three:

Safety of Rh Immunoglobulin Products -
Conference designed to focus on the concerns of the practicing OB/GYN presented by a physician thought leader

Topic Four:

Optimization of Rh Prophylaxis Treatment -
Conference designed for all specialties involved with the treatment of Rh related pregnancies

Following the lecture, there will be an interactive discussion on the clinical parameters and therapeutic options for pregnant women who are Rh-negative. A series of programs are being scheduled Monday through Thursday evenings. The entire program will last approximately one hour and you can participate in one of these sessions from either your office or your home.

For your participation in the telephone conference, and in compliance with AMA guidelines for promotional endeavors of this nature, you may choose to receive a medically relevant item with a retail value of $75 or less.

Teleconferences Dates

 
Click Here to Register Online Today

View all teleconference program dates.

Important Safety Information

Rhophylac® is indicated for suppression of rhesus (Rh) isoimmunization in:

  • Pregnancy and obstetric conditions in non-sensitized, Rho(D)-negative women with an Rh-incompatible pregnancy, including routine antepartum and postpartum Rh prophylaxis and Rh prophylaxis in cases of obstetric complications, invasive procedures during pregnancy, or obstetric manipulative procedures.
  • Incompatible transfusions in Rho(D)-negative individuals transfused with blood components containing Rho(D)-positive red blood cells.

For suppression of Rh isoimmunization, Rhophylac® can be administered IM or IV.

Rhophylac® is indicated to raise platelet counts in Rho(D)-positive, non-splenectomized adult patients with chronic immune thrombocytopenic purpura (ITP). For the treatment of ITP, Rhophylac® must be administered IV.

Rhophylac® is contraindicated in individuals with known anaphylactic or severe systemic reaction to human immune globulin products.

Allergic or hypersensitivity reactions may occur with Rhophylac®; early signs of hypersensitivity include generalized urticaria, chest tightness, wheezing, hypotension, and anaphylaxis. Individuals with selective IgA deficiency can develop antibodies to IgA and may develop severe hypersensitivity and anaphylactic reactions. For these individuals, weigh the expected benefits of treatment against the potential risks.

Rhophylac® is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Suppression of Rh Isoimmunization: For postpartum use following an Rh-incompatible pregnancy, Rhophylac® should not be given to the newborn infant.

The most common adverse reactions in the suppression of Rh isoimmunization with Rhophylac® are nausea, dizziness, headache, injection-site pain, and malaise.

Immune Thrombocytopenic Purpura: The most serious adverse reactions in patients receiving Rho(D) immune globulin have been observed in the treatment of ITP. ITP patients being treated with Rhophylac® should be monitored for signs and symptoms of intravascular hemolysis, including back pain, shaking chills, fever, and hemoglobinuria. Potentially serious complications of intravascular hemolysis include clinically compromising anemia, acute renal insufficiency, and, very rarely, disseminated intravascular coagulation, and death.

The most common adverse reactions observed in the treatment of ITP are chills, pyrexia/increased body temperature, and headache. Mild extravascular hemolysis has also been observed. In patients with preexisting anemia, weigh the benefits of Rhophylac® against the potential risk of increasing the severity of the anemia.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.